Comparative Pharmacology
Head-to-head clinical analysis: EPINEPHRINE versus LABETALOL HYDROCHLORIDE IN DEXTROSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPINEPHRINE versus LABETALOL HYDROCHLORIDE IN DEXTROSE.
EPINEPHRINE vs LABETALOL HYDROCHLORIDE IN DEXTROSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine is a direct-acting sympathomimetic amine that stimulates alpha-1, alpha-2, beta-1, beta-2, and beta-3 adrenergic receptors. Its effects include vasoconstriction (alpha-1), bronchodilation (beta-2), increased heart rate and contractility (beta-1), and relaxation of uterine and bladder smooth muscle.
Competitive antagonist at beta-1 adrenergic receptors (cardiac) and selective alpha-1 adrenergic receptors (vascular smooth muscle). Reduces heart rate, myocardial contractility, and peripheral vascular resistance.
0.3-0.5 mg IM (auto-injector or syringe) every 5-15 minutes as needed for anaphylaxis; IV: 0.1-0.5 mg (1-10 mcg/min infusion) for hemodynamic support.
Adult: Initial 0.5-2 mg/min IV infusion, titrate to response; typical maintenance 2-8 mg/min. Max cumulative dose 300 mg.
None Documented
None Documented
Clinical Note
moderateEpinephrine + Torasemide
"Epinephrine may increase the hypokalemic activities of Torasemide."
Clinical Note
moderateNorepinephrine + Torasemide
"Norepinephrine may increase the hypokalemic activities of Torasemide."
Clinical Note
moderateNorepinephrine + Etacrynic acid
"Norepinephrine may increase the hypokalemic activities of Etacrynic acid."
Clinical Note
moderateEpinephrine + Etacrynic acid
"Epinephrine may increase the hypokalemic activities of Etacrynic acid."
1-2 minutes (intravenous); clinical effect termination primarily due to rapid uptake and metabolism, not elimination half-life.
Terminal elimination half-life: 5-8 hours (adults); 8-12 hours (elderly); 2-4 hours (children). Clinical context: half-life may be prolonged in hepatic or renal impairment.
Primarily hepatic metabolism via catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO); renal excretion of metabolites (inactive) and small fraction (<5%) unchanged.
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~50% as metabolites; <5% unchanged in feces.
Category A/B
Category A/B
Alpha/Beta Agonist
Alpha/Beta-Blocker